About Fibrocell Science (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:FCSC
- CUSIP: N/A
- Web: www.fibrocell.com
Capitalization:- Market Cap: $41.21 million
- Outstanding Shares: 14,717,000
Average Prices:- 50 Day Moving Avg: $3.04
- 200 Day Moving Avg: $2.85
- 52 Week Range: $0.52 - $4.64
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.64
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $252,000.00
- Price / Sales: 163.52
- Book Value: ($0.75) per share
- Price / Book: -3.73
Profitability:- EBITDA: ($18,040,000.00)
- Return on Equity: -293.07%
- Return on Assets: -91.03%
Debt:- Current Ratio: 4.78%
- Quick Ratio: 4.78%
Misc:- Average Volume: 86,857 shs.
- Beta: 0.39
- Short Ratio: 3.46
Frequently Asked Questions for Fibrocell Science (NASDAQ:FCSC)
What is Fibrocell Science's stock symbol?
Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."
How were Fibrocell Science's earnings last quarter?
Fibrocell Science Inc (NASDAQ:FCSC) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.31). View Fibrocell Science's Earnings History.
When will Fibrocell Science make its next earnings announcement?
Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2017?
3 brokers have issued 1 year target prices for Fibrocell Science's shares. Their forecasts range from $2.00 to $7.60. On average, they expect Fibrocell Science's stock price to reach $5.53 in the next twelve months. View Analyst Ratings for Fibrocell Science.
Who are some of Fibrocell Science's key competitors?
Some companies that are related to Fibrocell Science include Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), Tissue Regenix Group PLC (TRX), Vernalis plc (VER), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), CytRx Corporation (CYTR), OvaScience (OVAS), Prima BioMed Ltd (PBMD), ReNeuron Group Plc (RENE), Sunesis Pharmaceuticals (SNSS), Bio-Path Holdings (BPTH), Senomyx (SNMX), Genocea Biosciences (GNCA), Abzena PLC (ABZA), Scancell Holdings Plc (SCLP) and Cleveland BioLabs (CBLI).
Who are Fibrocell Science's key executives?
Fibrocell Science's management team includes the folowing people:
- Douglas J. Swirsky, Chairman of the Board
- John M. Maslowski, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer
- Lisa A. Embon, Vice President - of Corporate Accounting , Controller
- Kelvin Moore, Lead Independent Director
- Julian P. Kirk, Director
- Marcus E. Smith, Director
- Marc B. Mazur, Independent Director
- Christine Thompson St.Clare, Independent Director
How do I buy Fibrocell Science stock?
Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fibrocell Science's stock price today?
One share of Fibrocell Science stock can currently be purchased for approximately $2.80.
MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Fibrocell Science (NASDAQ:FCSC)Earnings History by Quarter for Fibrocell Science (NASDAQ FCSC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | | | | | | | |
| 8/9/2017 | Q2 2017 | ($0.31) | ($0.31) | | | View | Listen |  |
| 5/10/2017 | Q1 2017 | ($0.29) | ($0.58) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.15) | ($0.05) | $0.07 million | $0.22 million | View | N/A | |
| 3/10/2016 | Q415 | ($0.17) | ($0.40) | $0.07 million | $0.08 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.07) | $0.06 million | $0.08 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.16) | ($0.17) | $0.09 million | $0.14 million | View | N/A | |
| 5/8/2015 | Q1 2015 | ($0.16) | ($0.17) | $0.05 million | $0.19 million | View | N/A | |
| 3/13/2015 | Q4 2014 | ($0.16) | ($0.16) | $0.06 million | $0.06 million | View | N/A | |
| 11/7/2014 | Q3 14 | ($0.14) | ($0.17) | $0.06 million | $0.02 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.18) | ($0.08) | $0.07 million | $0.06 million | View | N/A | |
| 5/19/2014 | Q114 | ($0.15) | ($0.35) | $0.05 million | $0.05 million | View | N/A | |
| 3/17/2014 | Q414 | ($0.26) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($1.01)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.31) | ($0.07) | ($0.19) |
| Q2 2017 | 4 | ($0.34) | ($0.07) | ($0.20) |
| Q3 2017 | 4 | ($0.35) | ($0.05) | ($0.20) |
| Q4 2017 | 3 | ($0.37) | ($0.05) | ($0.20) |
| Q1 2018 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q2 2018 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q3 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
(Data provided by Zacks Investment Research)
Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fibrocell Science (NASDAQ:FCSC)Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 54.70%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/2/2016 | David Pernock | Chairman | Buy | 50,000 | $0.92 | $46,000.00 | |
| 11/13/2015 | David Pernock | CEO | Buy | 3,000 | $5.00 | $15,000.00 | |
| 8/11/2015 | David Pernock | CEO | Buy | 3,500 | $6.54 | $22,890.00 | |
| 7/27/2015 | Randal J Kirk | Major Shareholder | Buy | 975,987 | $5.80 | $5,660,724.60 | |
| 5/13/2015 | David Pernock | CEO | Buy | 16,600 | $4.30 | $71,380.00 | |
| 12/12/2014 | David Pernock | CEO | Buy | 5,000 | $2.52 | $12,600.00 | |
| 11/20/2014 | David Pernock | CEO | Buy | 5,000 | $2.54 | $12,700.00 | |
| 11/20/2014 | John Michael Maslowski | VP | Buy | 1,000 | $2.54 | $2,540.00 | |
| 6/5/2014 | Christine St.Clare | Director | Buy | 10,000 | $3.00 | $30,000.00 | |
| 6/5/2014 | David Pernock | CEO | Buy | 12,500 | $2.95 | $36,875.00 | |
| 6/4/2014 | Kelvin Moore | Director | Buy | 4,557 | $2.99 | $13,625.43 | |
| 6/4/2014 | Randal J Kirk | Major Shareholder | Buy | 400,000 | $2.90 | $1,160,000.00 | |
| 1/24/2014 | Randal J Kirk | Major Shareholder | Buy | 1,024,590 | $4.88 | $4,999,999.20 | |
| 11/21/2013 | David Pernock | CEO | Buy | 10,000 | $3.69 | $36,900.00 | |
| 11/20/2013 | Gregory L Weaver | CFO | Buy | 10,000 | $3.51 | $35,100.00 | |
| 10/1/2013 | Randal J Kirk | Major Shareholder | Buy | 3,658,536 | $4.10 | $14,999,997.60 | |
| 7/26/2013 | Randal J Kirk | Major Shareholder | Buy | 1,243,781 | $6.03 | $7,499,999.43 | |
(Data available from 1/1/2013 forward)
Headline Trends for Fibrocell Science (NASDAQ:FCSC)
Latest Headlines for Fibrocell Science (NASDAQ:FCSC)
| Source: |
|
| Date | Headline |
|---|
 | Reviewing NovaBay Pharmaceuticals (NBY) & Fibrocell Science (FCSC)
www.americanbankingnews.com - October 20 at 6:46 AM |
 | Fibrocell Science: A Very Appealing Gene Therapy Play - Seeking Alpha
seekingalpha.com - October 19 at 7:21 PM |
| Fibrocell Science Inc (FCSC) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 7:40 PM |
| Fibrocell Science Inc (FCSC) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - October 5 at 10:08 AM |
| Brokerages Anticipate Fibrocell Science Inc (FCSC) to Announce -$0.41 Earnings Per Share
www.americanbankingnews.com - October 4 at 6:26 PM |
 | Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa
finance.yahoo.com - October 2 at 7:39 PM |
| HC Wainwright Raises Fibrocell Science Inc (FCSC) Price Target to $7.60
www.americanbankingnews.com - September 26 at 11:18 AM |
| Fibrocell Science (FCSC) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - September 25 at 12:26 AM |
 | Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options - Nasdaq
www.nasdaq.com - September 24 at 4:15 AM |
| Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options
finance.yahoo.com - September 23 at 9:44 AM |
| Fibrocell Science Inc (FCSC) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 17 at 10:22 PM |
| Analysts Expect Fibrocell Science Inc (FCSC) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - September 16 at 12:08 AM |
| Fibrocell Science Inc (FCSC) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - September 15 at 7:28 AM |
| Fibrocell Science (FCSC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 11 at 7:09 PM |
 | 10 Biggest Mid-Day Gainers For Friday - Benzinga
www.benzinga.com - September 8 at 7:03 PM |
| Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit
finance.yahoo.com - September 5 at 8:14 PM |
| Brokers Offer Predictions for Fibrocell Science Inc's Q1 2018 Earnings (FCSC)
www.americanbankingnews.com - August 14 at 6:58 AM |
| Fibrocell Science Inc (NASDAQ:FCSC) Posts Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - August 11 at 2:06 PM |
| Analysts Anticipate Fibrocell Science Inc (NASDAQ:FCSC) to Post -$0.31 EPS
www.americanbankingnews.com - August 10 at 8:06 AM |
| Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - August 9 at 6:47 PM |
| Fibrocell Science reports 2Q loss
finance.yahoo.com - August 9 at 6:46 PM |
| Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 3:40 PM |
| Fibrocell Science Inc (NASDAQ:FCSC) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - August 3 at 10:58 AM |
 | What's in Store for Intrexon (XON) in this Earnings Season?
www.zacks.com - August 2 at 7:29 PM |
| Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 2 at 7:29 PM |
| What's in Store for Intrexon (XON) in this Earnings Season?
finance.yahoo.com - August 2 at 7:29 PM |
| -$0.31 EPS Expected for Fibrocell Science Inc (NASDAQ:FCSC) This Quarter
www.americanbankingnews.com - July 20 at 10:15 PM |
 | XLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA Snubs CHRS
www.rttnews.com - June 13 at 11:33 AM |
 | Fibrocell Science (FCSC) Announces Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
www.streetinsider.com - June 13 at 11:33 AM |
 | Why 2 rare pediatric disease designations could bring big bucks for Exton gene therapy developer
www.bizjournals.com - June 12 at 6:01 PM |
| Fibrocell Science (FCSC) Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
www.streetinsider.com - June 8 at 6:11 PM |
| Fibrocell Science's (FCSC) CEO John Maslowski on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:44 PM |
| Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat
www.zacks.com - May 11 at 5:46 PM |
 | Fibrocell Science reports 1Q loss
marketbeat.com - May 10 at 8:33 AM |
| Fibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB
www.streetinsider.com - May 8 at 9:03 AM |
| Fibrocell Science Inc. (FCSC) Has Climbed To A 1-Month High
www.rttnews.com - April 13 at 11:14 AM |
| Fibrocell Science (FCSC) Announces Compliance with NASDAQ Listing Requirements
www.streetinsider.com - March 28 at 11:50 AM |
| Fibrocell Science (FCSC) Plans 1-for-3 Reverse Stock Split
www.streetinsider.com - March 10 at 11:18 AM |
 | Fibrocell Announces One-for-Three Reverse Stock Split
us.rd.yahoo.com - March 10 at 11:18 AM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articl
biz.yahoo.com - March 10 at 11:18 AM |
| Q4 2016 Fibrocell Science Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 5:38 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - March 9 at 5:38 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fin
biz.yahoo.com - March 8 at 5:58 PM |
| Benzinga's Top Upgrades, Downgrades For March 7, 2017 - Benzinga
www.benzinga.com - March 8 at 8:05 AM |
| 4:55 pm Fibrocell Science entered into securities purchase agreement with existing investors for sale of $8.0 mln Series A Convertible Preferred Stock and accompanying warrants
us.rd.yahoo.com - March 7 at 11:11 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
biz.yahoo.com - March 3 at 11:50 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
us.rd.yahoo.com - March 1 at 9:54 PM |
| Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
us.rd.yahoo.com - February 23 at 5:11 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 13 at 9:38 AM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 5:59 PM |
Fibrocell Science (FCSC) Chart for Friday, October, 20, 2017
